Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reached, it would rank among the largest disclosed patent settlements in biopharmaceutical industry history.
The post Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology appeared first on MedCity News.
